v3.26.3
Joint Venture - Additional Information (Detail)
$ in Thousands, ¥ in Billions
 3 Months Ended 9 Months Ended
Jul. 18, 2024
USD ($)
Jul. 18, 2024
JPY (¥)
May 18, 2024
USD ($)
May 18, 2024
JPY (¥)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jul. 18, 2024
JPY (¥)
Schedule of Equity Method Investments [Line Items]                    
Accounts receivable [1]         $ 380,744   $ 380,744   $ 311,170  
Deferred other income [2]         11,966   11,966   15,955  
Net revenue         411,537 $ 334,206 1,142,139 $ 904,578    
Deferred revenue [3]         85,931   85,931   92,673  
S B Tempus Corp [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Accounts receivable         318   318   173  
Deferred revenue         0   0   6,235  
Joint Venture Agreement [Member] | S B Tempus Corp [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Joint venture formation date     May 18, 2024 May 18, 2024            
Common stock value $ 95,200                 ¥ 15.0
Investment         77,600   77,600      
Accounts receivable         300   300   200  
Joint Venture Agreement [Member] | S B Tempus Corp [Member] | Investment in SB Tempus Pursuant to Joint Venture Agreement [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Equity method investment ownership percentage 50.00%                 50.00%
Data License Agreement [Member] | S B Tempus Corp [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Proceeds from license fees     $ 47,900 ¥ 7.5            
Net revenue         0 6,200 6,200 18,700    
Deferred revenue         0   0   6,200  
Intellectual Property License Agreement [Member] | S B Tempus Corp [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Proceeds from license fees $ 47,900 ¥ 7.5                
Payment in deferred other income amortized in to other expense period 3 years 3 years                
Deferred other income         12,000   12,000   16,000  
Deferred other income less current portion         0   0   $ 8,000  
Income from license agreement recognized         $ 4,000 $ 4,000 $ 12,000 $ 12,000    
[1] Includes related party accounts receivable from Pathos AI, Inc. of $12,092 and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party accounts receivable from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture.
[2] Deferred other income balances solely related to SB Tempus Corp. Refer to Note 7, Joint Venture
[3] Includes related party deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party deferred revenue from SB Tempus Corp. of $0 and $6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture.